Revenue Breakdown
Composition ()
No data
Revenue Streams
Organogenesis Holdings Inc (ORGO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Advanced Wound Care, accounting for 92.0% of total sales, equivalent to $92.70M. Another important revenue stream is Surgical & Sports Medicine. Understanding this composition is critical for investors evaluating how ORGO navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Organogenesis Holdings Inc maintains a gross margin of 30.77%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -185.05%, while the net margin is -142.78%. These profitability ratios, combined with a Return on Equity (ROE) of -5.97%, provide a clear picture of how effectively ORGO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ORGO competes directly with industry leaders such as YDES and PROF. With a market capitalization of $299.81M, it holds a significant position in the sector. When comparing efficiency, ORGO's gross margin of 30.77% stands against YDES's -43.90% and PROF's 71.80%. Such benchmarking helps identify whether Organogenesis Holdings Inc is trading at a premium or discount relative to its financial performance.
